Disclosure NewswireTMiCrowdNewswire - Mar 14, 2018
NEW YORK, — WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on AMRN, APRI, UTHR, and NVO which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), United Therapeutics Corp. (NASDAQ: UTHR), and Novo Nordisk A/S (NYSE: NVO). Companies in the Drug Manufacturers category are focused on the research, distribution, and marketing of pharmaceutical drug products. All you have to do is sign up today for this free limited time offer by clicking the link below.
On Tuesday, shares in Dublin, Ireland-based Amarin Corp. PLC recorded a trading volume of 1.78 million shares. The stock ended at $3.75, rising 2.18% from the last trading session. The Company’s shares have gained 7.76% in the last month, 15.38% over the previous three months, and 18.67% over the past year. The stock is trading above its 200-day moving average by 6.14%. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 54.97.
On March 12th, 2018, Amarin announced the presentation of a poster that day at the American College of Cardiology 67th Annual Scientific Session and Expo in Orlando, Florida. This analysis reinforces that statin-treated patients at high CV risk with controlled LDL-cholesterol (LDL-C) and elevated triglyceride (TG) levels, TG ≥ 150 mg/dL, had worse CV outcomes and higher overall healthcare costs than statin-treated patients with controlled LDL-C and normal TG levels, TG <150 mg/dL, and normal HDL-cholesterol, HDL-C > 40 mg/dL. Get the full research report on AMRN for free by clicking below at:
San Diego, California headquartered Apricus Biosciences Inc.’s stock finished yesterday’s session 0.98% higher at $0.80with a total trading volume of 407,486 shares. The stock is trading below their 200-day moving average by 49.95%. Shares of the Company, which focuses on the development and commercialization of product candidates in the areas of urology and rheumatology, have an RSI of 30.58.
On February 16th, 2018, research firm H.C. Wainwright downgraded the Company’s stock rating from ‘Buy’ to ‘Neutral’, with a target price of $1 per share.
On February 16th, 2018, Apricus Biosciences announced that the US FDA has issued a complete response letter (“CRL”) for the New Drug Application (“NDA”) of VitarosTM (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction. The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. The free technical report on APRI can be accessed at:
At the close of trading on Tuesday, shares in Silver Spring, Maryland headquartered United Therapeutics Corp. saw a decline of 1.88%, ending the day at $113.89. The stock recorded a trading volume of 283,738 shares. The Company’s shares are trading 11.41% below their 200-day moving average. Moreover, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 37.94.
On February 21st, 2018, United Therapeutics announced its results for the quarter and year ended December 31st, 2017. For Q4 2017, net revenues were $464.7 million; net income was $19.0 million; and total R&D expense $113.6 million. For the full year 2017, net revenues were $1,725.3 million; net income was $417.9 million; and total R&D expense was $264.6 million.
On February 22nd, 2018, research firm Barclays reiterated its ‘Underweight’ rating on the Company’s stock with a decrease of the target price from $115 a share to $105 a share. Sign up for free on Wall St. Equities and claim the latest report on UTHR at:
Bagsvaerd, Denmark headquartered Novo Nordisk A/S’s shares ended the day 1.06% lower at $50.33. A total volume of 2.44 million shares was traded, which was above their three months average volume of 1.45 million shares. The stock has gained 0.52% in the last month and 48.77% over the past year. The Company’s shares are trading 3.46% above their 200-day moving average. Additionally, shares of Novo Nordisk, which engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide, have an RSI of 42.04.
On March 05th, 2018, Novo Nordisk announced that Ozempic® (semaglutide injection) is now available across Canada. Ozempic® is a once-weekly, glucagon-like peptide receptor agonist indicated alongside diet and exercise to improve glycemic control in adults with type 2 diabetes when metformin is inappropriate. See the free research coverage on NVO at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit